India’s Pharma First: Biophore Secures CDSCO Approval for Synthetic CBD in 2023
Hyderabad-based Biophore becomes first Indian firm cleared to manufacture cannabidiol oral solution.
In May 2023, Biophore achieved a milestone by becoming the first Indian company to receive CDSCO approval to manufacture a synthetic cannabidiol (CBD) oral solution — a move that could reshape India’s medical cannabis landscape.
India’s medical cannabis sector took a giant leap forward in May 2023 when Hyderabad-based pharmaceutical company Biophore received approval from the Central Drugs Standard Control Organisation (CDSCO) to produce a synthetic cannabidiol (CBD) oral solution.
The decision marked the first time in India that a domestic company was formally cleared to develop a regulated CBD drug, moving the conversation from startups and wellness brands to big pharma.
Industry observers said the Biophore CBD approval India 2023 could open the door for new medical cannabis research, clinical trials, and pharmaceutical innovation. Doctors and policymakers noted that a CDSCO-backed solution would give the space more legitimacy, especially in treating conditions like epilepsy, anxiety, and cancer-related pain.
Pharma analysts added that this milestone places India closer to global leaders in CBD-based medicine, signaling an era where medical cannabis may become part of structured healthcare rather than just alternative wellness.
Referance
